Ñî¹óåú´«Ã½

PHILADELPHIA, January 25, 2022 – The Ñî¹óåú´«Ã½ issued an updated on the antibody response to SARS-CoV-2 after initial infection and protection against reinfection with SARS-CoV-2. The new version, What is the Antibody Response and Role in Conferring Natural Immunity Following SARS-CoV-2 Infection? Rapid, Living Practice Points from the Ñî¹óåú´«Ã½ (Version 2), was published today in Annals of Internal Medicine.

Guidelines highlight opportunity to manage most patients with uncomplicated disease in outpatient settings and to initially manage select patients without antibiotics. Patients with complicated disease should be referred for colonoscopy after initial episode if they have not had a recent colonoscopy.

Statement attributable to:
George M. Abraham, MD, MPH, MACP, FIDSA
President, Ñî¹óåú´«Ã½

WASHINGTON, D.C. January 14, 2022 –The Ñî¹óåú´«Ã½ (ACP) is disappointed that the Medicare Payment Advisory Commission (MedPAC) voted yesterday on recommendations to effectively freeze physician payments in the upcoming year. This recommendation comes at a time when physicians are still reeling from the COVID-19 pandemic and confronting a crushing wave of patients with new COVID-19 infections.

Statement attributable to:
George M. Abraham, MD, MPH, MACP, FIDSA
President, Ñî¹óåú´«Ã½

WASHINGTON, D.C. January 14, 2022 –The Ñî¹óåú´«Ã½ (ACP) is relieved that yesterday’s announcement from the Supreme Court allows COVID-19 vaccination requirements to go into effect for health care workers, but extremely disappointed that it does not do the same for requirements of other employers.

Statement attributable to:
Thomas G. Cooney, MD, MACP
Chair, Board of Regents
Ñî¹óåú´«Ã½

Statement attributable to:
Thomas G. Cooney, MD, MACP
Chair, Board of Regents
Ñî¹óåú´«Ã½

WASHINGTON, D.C. December 20, 2021 –The Ñî¹óåú´«Ã½ (ACP) supports the Biden administration announcement of new efforts to limit greenhouse gas emissions from cars and SUVs. Climate change and poor air quality harm health and reducing pollutants in the air could help to limit the occurrence of, and symptoms for those with, cardiovascular and respiratory diseases.

Panel answers challenging clinical questions about COVID-19 variants, vaccines, and therapeutics